For Immediate Release
Chicago, IL – August 27, 2012 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include BioDelivery Sciences International Inc. (Nasdaq:BDSI), Reckitt Benckiser Group Plc (OTC:RBGPY), Endo Health Solutions Inc. (Nasdaq:ENDP), HSBC Holdings plc (NYSE:HBC) and Moody’s Corporation (NYSE:MCO)
Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513
Here are highlights from Friday’s Analyst Blog:
Pipeline Progress at BioDelivery
BioDelivery Sciences International Inc. (Nasdaq:BDSI) recently announced that it has finished enrolling patients in a pivotal pharmacokinetic study (BNX
103) being conducted with BEMA buprenorphine/naloxone (BNNX). The company also announced the completion of the clinical portion of the study. BNX is being evaluated for the treatment of opioid dependence.
Study participants have already been dosed and a plasma sample analysis is being conducted. BioDelivery intends to present results from the study before the end of September 2012.
According to an agreement with the US Food and Drug Administration (:FDA), in February 2012, BNX-103 was designed to compare the relative bioavailability of buprenorphine and naloxone with the reference drug of Reckitt Benckiser Group Plc’s (OTC:RBGPY) Suboxone.
BioDelivery expects the open-label safety study for the program BNX-103, to be completed by the end of 2012. Necessary product stability data from the study are expected to be available by the first quarter of 2013. The company is also planning for submission of the New Drug Application (:NDA) in the second quarter of 2013.
We note that in January 2012, Endo Health Solutions Inc. (Nasdaq:ENDP) inked a global license and development agreement with BioDelivery Sciences regarding the latter’s pain candidate BEMA buprenorphine. As per the terms of the deal, Endo Health Solutions is responsible for the manufacturing, distribution and commercialization of the candidate on a worldwide basis.
Following the deal, BioDelivery Sciences has received $30 million as an upfront payment. The $15 million payable by Endo Health Solutions, on the extension of BEMA buprenorphine’s patent protection period will result in Endo Health Solutions making payments worth $45 million under the deal. BioDelivery Sciences is eligible to receive a further $135 million in milestone payments in addition to royalties from Endo Health Solutions.
Currently, we have a Neutral recommendation on BioDelivery Sciences, which carries a Zacks #3 Rank (short-term ‘Hold’ rating).
S&P Lowers HSBC's Rating Outlook
On Thursday, Standard & Poor’s Ratings Services (S&P) downgraded its outlook on HSBC Holdings plc (NYSE:HBC) and its other rated holding companies to ‘Negative’ from ‘Stable’.
The downward revision was propelled by the company’s failure to abide by regulatory compliances, including the rules related to U.S. anti-money laundering standards. However, it affirmed the 'A+/A-1' long- and short-term counterparty credit ratings for HSBC and other units.
Apart from inquiry over anti-money laundering (:AML) standards, the bank was also accused of selling payment protection insurance (:PPI) and interest rate hedging products in the U.K. in a misappropriate manner.
Moreover, the bank has been accused of breaching rules related to U.S.
mortgage foreclosure practices.
After year-long investigations into HSBC’s compliance with anti-money laundering rules, the subcommittee alleged that the bank failed to meet the rules. This could possibly result in hefty penalties. Apart from the senatorial committee, the Department of Justice and the Office of Foreign Asset Control are also probing the bank.
The investigation revealed substantial lapses in the bank's anti-money laundering compliance. This resulted in a worldwide displacement of funds from riskier nations through the bank and indicates prospective failure of HSBC’s enterprise risk management.
According to S&P, the actions on the part of U.S. regulators are uncertain. Therefore, HSBC has kept aside about $700 million to meet regulatory fines. As of the six months ended June 30, 2012, HSBC has also made provisions of $2 billion for regulatory fines and associated costs over $1.1 billion made in 2011.
Moreover, HSBC is already facing an enquiry related to the London Interbank Offered Rate, or the LIBOR. Although the bank is not officially charged for any wrongdoing, it is feared that such allegations and investigations might tarnish the goodwill of the company.
Last month, HSBC reported results for the first half of 2012 with its net income declining nearly 7% year over year. Additionally, factors that continue to persist include the impact of the deepening Euro-zone crisis, various investigations related to its business operations and regulatory restrictions on its financials.
All these negative issues related to the bank, along with S&P’s reassessment of HSBC’s capabilities, resulted in a downward revision.
According to S&P, upgrading the rating outlook to stable depends on certain factors. These include senior management’s full control over the bank’s activities and insignificant after-effects of the recent issues.
Moreover, HSBC’s balance sheet position remains intact, which would facilitate the bank to survive amidst the volatile global economic conditions.
Moreover, other rating agencies such as Fitch Ratings and Moody’s Investor Service – the rating arm of Moody’s Corporation (NYSE:MCO) – have a negative outlook on HSBC.
Though HSBC is working to address such issues, further rating downgrades could be implemented following pressure on the bank’s trading business and profitability from regulatory intrusion or client discontent. Moreover, this rating downgrade will affect investors’ confidence in the stock, depicting the legal issues faced by the company.
Currently, the harsh impact of the deepening Euro-zone crisis is our primary concern. Moreover, HSBC is suffering from a weak revenue growth in its mature markets, attributable to the ongoing low interest rates and regulatory restrictions. However, the company is poised to benefit from its extensive global network, strong capital position, business re-engineering efforts and strong asset growth.
HSBC currently retains a Zacks #3 Rank, which translates into a short-term Hold rating. Considering the fundamentals, we also maintain a long-term ‘Neutral’ recommendation on the stock.
Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: http://at.zacks.com/?id=5515.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today: http://at.zacks.com/?id=5517
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leon Zacks. As a PhD from MIT Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=5518.
Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Follow us on Twitter: https://twitter.com/zacksresearch
Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
Zacks Investment Research
800-767-3771 ext. 9339
More From Zacks.com